EICHORPublic-registry site landscape for NCT02794155, “Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)”, a Type 1 Diabetes Mellitus study sponsored by Diasome Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02794155 (registry record) |
| Study title | Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) |
| Official title | Phase 2b, Multicenter, Randomized, Double Blind, Titration Trial for Efficacy and Safety of HDV Insulin Lispro in Combination With a Basal Insulin Versus Insulin Lispro in Combination With a Basal Insulin in Patients With Type 1 Diabetes |
| Sponsor | Diasome Pharmaceuticals |
| Condition(s) | Type 1 Diabetes Mellitus |
| Phase | PHASE2 |
| Listed sites | 21 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02794155.
Eichor generates a preliminary site-risk snapshot for NCT02794155 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type 1 Diabetes Mellitus trials
More from Diasome Pharmaceuticals
← Eichor home · All tracked trials · Type 1 Diabetes Mellitus studies · Weekly briefs
